Pancreatic cancer screening for people at high risk — who is offered it, and what it involves

The phrase people type is pancreatic cancer screening high risk, and behind it sits one plain question: is there a scan I can ask for? For the general population, no. There is no blood test, no scan and no programme that looks for pancreatic cancer in people at ordinary risk, and none is recommended anywhere. What exists instead is narrower and more useful — a structured surveillance programme offered only to people whose inherited or familial risk is high enough to justify putting them through it.

The reasoning is worth understanding, because it is not about cost. The pancreas sits deep in the abdomen, behind the stomach, and an early tumour there is small and silent. A test applied to a whole population would turn up far more harmless cysts and indeterminate spots than cancers, and every one of those leads to another scan, sometimes a procedure, and a stretch of real fear. A screening test earns its place only when the people being tested are likely enough to have the disease that finding it outweighs the harm of everything else the test drags up.

The blood test people ask for by name is CA 19-9, and it is worth saying clearly that it is not a screening test. It can be entirely normal in someone who has pancreatic cancer, and it can be raised by things that are not cancer at all, such as gallstones or a blocked bile duct. Inside a surveillance programme it is sometimes tracked as a trend alongside imaging. On its own, in a well person, it answers nothing. The wider picture of the disease is set out in our complete guide to pancreatic cancer.

So this page does not answer “can I be screened?” with a yes or a no. It answers the three questions that actually follow: who structured pancreatic cancer surveillance is offered to, what a year inside that programme involves, and what it genuinely can and cannot do for you.

• Two or more first-degree relatives — parents, brothers, sisters or children of one another — have had pancreatic cancer. This is the clearest reason to have the family assessed, and what the pattern means is set out in familial pancreatic cancer.
• One of your parents or siblings was affected, and so was a first-degree relative of theirs. You may sit inside a familial kindred even though only one person close to you was diagnosed.
• A relative was tested, a gene change was found, and nobody has explained what it means for you. Getting the actual laboratory report matters more than any amount of family recollection.
• Anyone in the family was diagnosed unusually young. Age at diagnosis moves the assessment more than the raw number of affected relatives does.
• Pancreatic cancer sits alongside breast, ovarian, prostate or bowel cancer, or melanoma, on one side of the family. That combination points at a named inherited syndrome, and it changes which test is the right one to do first.
• You have been told elsewhere that you are high risk, and want to know what the programme involves before committing to it. Surveillance is a commitment measured in years, and it is reasonable to understand it before starting.
• You smoke, and pancreatic cancer runs in your family. This is the one factor on this page that is in your own hands, and it deserves saying out loud rather than leaving implied.

1. 1

   Eligibility decided before anything is scanned

   The first appointment is a free 45-minute consultation and a conversation, not a battery of tests. We draw the family out on paper — who was affected, on which side, how they were related to one another, roughly when, and which other cancers appear in the same bloodline — and check that shape against the published criteria.

   In-house at CION
2. 2

   Genetic counselling, and testing where it changes the answer

   For many people the germline result is what decides eligibility, so counselling comes first — you should know what each possible result would and would not mean before the sample is taken. The blood or saliva sample is arranged through that session; the laboratory analysis itself is done by a specialist genetics laboratory.

   Counselling in-house at CION; laboratory analysis external
3. 3

   A baseline scan that maps the whole gland

   Surveillance usually opens with contrast MRI and MRCP, which shows the gland and the duct system in detail without radiation — what the study involves is explained in MRI and MRCP for the pancreas and bile ducts. Everything afterwards is read against this baseline rather than in isolation.

   In-house at CION
4. 4

   Endoscopic ultrasound, at a partner endoscopy service

   An ultrasound probe on the tip of an endoscope sits close enough to the pancreas to pick up small solid changes that cross-sectional imaging can miss, and it is the only part of the programme that can also sample tissue — see endoscopic ultrasound and EUS-FNA biopsy. CION does not perform this in-house.

   Coordinated with partner endoscopy centres; may be billed there
5. 5

   Repeat imaging at a set interval

   While everything stays unchanged, imaging repeats on a fixed schedule, typically once a year, with MRI and endoscopic ultrasound alternated or combined according to the programme you are on. CA 19-9 may be checked alongside as a trend rather than a verdict. Imaging carries the programme; the blood test does not.

   MRI, CT and bloods in-house at CION; EUS coordinated
6. 6

   A clear plan when something shows up

   Most findings are small cysts or indeterminate spots that turn out to be nothing, and the usual response is a shorter interval to see whether anything changes. Where a finding is genuinely suspicious, the pathway moves quickly — sampling, staging and a treatment discussion, rather than another year of waiting.

   Decision in-house at CION; biopsy, staging and surgery coordinated

You will otherwise find this out at the wrong moment, so here is the split. The consultation, the family-history and pedigree assessment, genetic counselling and the eligibility decision itself are delivered in-house at CION across our 35+ centres, as are pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods — ordered and reported by us. Endoscopic ultrasound is not done in-house. It is coordinated with specialist gastroenterology and endoscopy partner centres, and may be billed there. The same is true of any biopsy taken during that procedure, of ERCP and biliary stenting, of staging laparoscopy, of PET-CT and DOTATATE PET, and of every pancreatic operation. We say this before a programme starts rather than after the first bill arrives.

It is also worth being honest about the trade. Surveillance can find a change at a point where something can still be done about it, and in a genuinely high-risk family that is a realistic goal rather than a hope. It also finds things that turn out to be nothing — small cysts and indeterminate spots that lead to extra scans, sometimes an extra procedure, and a stretch of real worry before they are dismissed. That cost is exactly why the criteria are narrow, and why nobody at ordinary risk is put through it.

And it is a commitment measured in years rather than a single test. Whether to start, and whether to keep going, is a decision worth taking with that in mind, and it can be revisited. Reasons to pause or stop — other health problems, or reaching a point where an operation would no longer be a reasonable option — are legitimate, and they are discussed openly rather than left to drift.

A scan on a schedule covers the day it is done. It does not cover the months in between, and it is not a reason to sit on something that has changed. Symptoms are assessed on the story they tell, never on where you happen to sit in a scan calendar — and a clear scan a few months ago is not an answer to a new symptom today.

One sign needs checking that same week whether you are in a surveillance programme or not: painless yellowing of the eyes or skin, often with dark urine and pale stools. Jaundice without pain is the sign that earns an urgent appointment. Alongside it, a lower threshold is sensible for unintended weight loss, for a new upper-abdominal or back pain that keeps returning, and for diabetes appearing for the first time in later life, particularly where weight is falling at the same time. None of these means cancer. Each means get it looked at properly rather than waiting it out.

The other thing surveillance does not do is change your risk. It watches; it lowers nothing. Stopping smoking does, and inside a high-risk family it is the single factor that stacks on top of the inherited pattern and the only one anybody can put down. If there are smokers in your family, that conversation is worth more than another evening of reading.

Medical disclaimer: This page explains who is offered structured pancreatic cancer surveillance and what such a programme involves, and is reviewed by a CION medical oncologist with reference to NCCN guidance on genetic and familial high-risk assessment and to international consensus recommendations on surveillance in high-risk individuals. It is general information and not a risk assessment for any individual or family; whether surveillance applies to you should be decided with a doctor and a genetic counsellor who know your history. The free 45-minute consultation, family-history and pedigree assessment, genetic counselling, the eligibility decision, diagnostic ordering and reporting (pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods), medical and radiation oncology, nutrition and enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION; germline laboratory analysis is performed by an external specialist genetics laboratory. Endoscopic ultrasound and EUS-FNA biopsy, ERCP and biliary stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, PRRT and all pancreatic surgery are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.